DOCSLIB.ORG

Fullsubwaymap221.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Fullsubwaymap221.Pdf A B C D E F G H I J K L M Aldose reductase Sorbitol dehydrogenase Cholesterol synthesis Glycogen and galactose metabolism (branch point only) (debranching) glucose sorbitol fructose Aromatic amino acid metabolism Purine synthesis Pyrimidine synthesis glycogen (n+1) phenylacetate triiodothyronine (T3) dopaquinone melanin + + thyroxine (T4) (multiple steps) (many cycles) P 4' NADPH NADP NAD NADH acetyl-CoA x2 i Debranching enzyme 3' - α-1,4 bonds Aromatic amino acid 5-phosphoribosyl pyrophosphate (PRPP) HCO B 2' P 3 (branching) Glycogen 6 i (multiple steps) O H O (multiple steps) Tyrosinase O H O 1' 2 2 2 2 B 1 2 3 4 5 6 7 8 9 10 Pentose phosphate pathway Phenylalanine Tyrosine decarboxylase 6 Dopamine B Thiolase phosphorylase -5 -4 -3 -2 -1 0 1 2 3 4 Transaminase 6 glutamine 2 ATP (many cycles) Glycogen Glucose-6-phosphatase Dehydrogenase hydroxylase hydroxylase (DOPA decarboxylase) β-hydroxylase Methyltransferase 10 UDP 4:4 Transferase ATP glutathione (reduced) H O phenyllactate phenylpyruvate phenylalanine tyrosine dihydroxy- dopamine Glutamine PRPP CoA synthase Hexokinase or (in endoplasmic reticulum) 2 2 norepinephrine epinephrine glutamine Carbamoyl 9 1' phenylanine amidotransferase (GPAT) glutamate glycogen (n) Glutathione reductase Glutathione peroxidase + phosphate glycogen (n) -5 -4 -3 -2 -1 0 1 2 3 4 2' 3' 4' glucokinase 8 NADP NADPH glutamate α-ketoglutarate CO2 O H O Glycosyl (4:6) UDP-glucose ADP (L-DOPA) 2 2 synthetase II glutathione (oxidized) 2 H O α-ketoglutarate PPi glutamate acetoacetyl-CoA 7 1 Glucose -1,6-Glucosidase 2 SAM SAH transferase α B (CPSII) 1' Transaminase 6 6 (free) (in lysosomes) + + (branching α-1,6 bond conjugated UTP glucose- + NADP NADPH NADP NADPH 1 2 3 4 5 NADP NADPH biosynthetic reduction reactions glutamate acetyl-CoA -5 -4 -3 -2 -1 0 1 2 3 4 2' 3' 4' H O H+ homovanillic acid (HVA) vanillylmandelic acid (VMA) VMA 2 ADP P HMG-CoA synthase enzyme) bilirubin PP UTP 1-phosphate 2 i 1 i Tetrahydrobiopterin (BH4) Dihydrobiopterin (BH2) BH4 BH2 5-phosphoribosylamine 1 uridyltransferase Phosphoglucomutase Dihydrobiopterin p-hydroxyphenylpyruvate Dihydrobiopterin 6-phosphogluconolactone 6-phosphogluconate + CoA glucose-1-phosphate glucose-6-phosphate NADP glycine Steroid hormone synthesis Glucose-6-phosphate Lactonase reductase reductase ATP other NADPH O carbamoyl phosphate primed glycogenin UDP-galactose epimerase dehydrogenase (G6PD) 6-Phosphogluconate 2 p-hydroxyphenylpyruvate GAR synthetase β-hydroxy-β-methylglutaryl-CoA glucuronidation (multiple steps) ADP Glycolysis and Gluconeogenesis dehydrogenase dioxygenase Aromatic amino acid (HMG-CoA) reactions CO O H O Aspartate CO 2 2 Tryptophan 2 decarboxylase B6 Serotonin Hydroxyindole UDP-glucose UDP-galactose 2 P aspartate Zona glomerulosa (8 cycles) glucose hydroxylase (DOPA decarboxylase) N-acetyltransferase O-methyltransferase i transcarbamoylase HMG-CoA reductase 2 NADPH glycogenin Lactose synthase fructose 2,6-bisphosphate AMP Galactose-1-phosphate alkapton homogentisate N-acetyl-5-HT melatonin UDP-glucose UDP (inside Golgi of nucleotides 5-phosphoribosyl pyrophosphate (PRPP) ATP ribulose-5-phosphate Dihydroneopterin tryptophan 5-hydroxy- serotonin (5-HT) cholesterol uridyltransferase (GALT) ADP Phosphoglucose (spontaneous) glycinamide ribonucleotide P CoA + dehydrogenase triphosphate tryptophan i 2 NADP UDP mammary cells) Phosphofructokinase-2 ATP isomerase PRPP synthetase O Homogentisate CO acetyl-CoA CoA (GAR) UDP-glucuronate Ribose-5- 2 2 lactose Fructose bisphosphatase-2 dioxygenase SAM SAH phosphate niacin Cholesterol 2 NADH 2 NAD+ (Bifunctional enzyme) formate N10-formyl-THF N-carbamoyl aspartate mevalonate galactose-1-phosphate isomerase NADP+ NADPH Monoamine GAR transformylase desmolase Phosphomannose GTP-cyclohydrolase maleylacetoacetate oxidase (MAO) glycosaminoglycans (GAGs) ADP sedoheptulose- BH BH THF Zona fasciculata and zona reticularis Hexokinase isomerase ribose-5-phosphate Ribulose-5- H O 4 2 (multiple 3 ATP glycoproteins mannose mannose-6-phosphate fructose-6-phosphate 2 Dihydroorotase Galactokinase 7-phosphate phosphate Maleylacetoacetate Dihydrobiopterin steps) glycolipids NADP+ NADPH ATP succinylacetoacetate (spontaneous) 17α-hydroxylase 17, 20 lyase epimerase isomerase reductase ATP ADP GTP formyl-GAR 3 ADP pregnenolone 17-hydroxypregnenolone dehydroepiandrosterone galactitol galactose 5-hydroxyindoleacetic acid glutamine 6 7 7 5 (spontaneous) (FGAR) dihydroorotate (DHEA) Aldose reductase B CO fumarylacetoacetate P + + Transaldolase + + Transketolase 1 2 CO glutamate ATP i 2 3β-hydroxysteroid 3 -hydroxysteroid 3β-hydroxysteroid 4 3 3 5 β Fructose-1,6- H O Fumarylacetaoacetate ATP dehydrogenase dehydrogenase dehydrogenase Phosphofructokinase-1 succinylacetone 2 Glutamine: F6P bisphophatase hydrolase NAD+ isopentenyl pyrophosphate (IPP) GAGs glucosamine- 6-phosphate B ADP glyceraldehyde- FGAM synthetase Dihydroorotate aminotransferase 6 erythrose- ADP (step 2) (step 1) xylulose-5-phosphate Methionine adenosyltransferase dehydrogenase (C5) x3 17α-hydroxylase 17, 20 lyase Aromatase 4-phosphate 3-phosphate progesterone 17-hydroxyprogesterone androstenedione 6 4 TCA acetoacetate fumarate TCA Pi NADH (in mitochondria) estrone B Coenzyme Q Coenzyme Q Transketolase 1 + + 17β-hydroxysteroid (reduced) (oxidized) 3 5 ATP 3 P H O (multiple 21-hydroxylase 21-hydroxylase fructose-1,6-bisphosphate i 2 2 PP dehydrogenase 17β-HSD glutamine i steps) (not in gonad) (not in gonad) (in mitochondrial matrix) orotate (17β-HSD) (step 3) methionine S-adenosylmethionine (SAM) FAD FADH Aromatase 2 Single-carbon metabolism and sulfur-containing amino acids glutamate 2 farnesyl pyrophosphate (FPP) 11-deoxycorticosterone 11-deoxycortisol testosterone estradiol 2 (11-DOC) PRPP Orotate (C15) x2 11 -hydroxylase Mitochondrial glycerol Aldolase Methyltransferases β CH (used for methylation) phosphoribosyl- 11β-hydroxylase 3-phosphate dehydrogenase (avoprotein) purine synthesis histidine catabolism pyrimidine synthesis 3 formiminoglycinamidine ribonucleotide (FGAM) PP transferase 5 reductase Glycerol i Squalene synthase NADPH α corticosterone cortisol dihydrotestosterone (DHT) kinase Glycerol-3-phosphate dehydrogenase ATP + glycerol glycerol dihydroxyacetone glyceraldehyde- Homocysteine B 11β-hydroxysteroid NAD NADH THF 12 S-adenosylhomocysteine (SAH) AIR synthetase + 3-phosphate 2 PP NADP Aldosterone dehydrogenase 2 (11β-HSD2) 3-phosphate + phosphate (DHAP) Triosephosphate isomerase methyltransferase orotidine-5'-mono- i ATP ADP NAD NADH + synthase NADPH NADP+ NADPH NADP+ formate ATP ADP H O NADPH NADP NADPH NADP+ ADP cortisone Pi 2 S-adenosyl- phosphate (OMP) 10 5 10 5 10 5 homocysteine + B Pi 11β-HSD1 Fructose-1-P aldolase Triose kinase ADP Pi 9 folate dihydrofolate tetrahydrofolate N -formyl-THF N ,N -methenyl-THF N ,N -methylene-THF N -methyl-THF squalene (C30) aldosterone + NAD hydrolase NADP NADPH Fructokinase (aldolase B) Dihydrofolate DHFR (THF) C1-THF Methenyl-THF Methenyl-THF Methylene-THF ATP Glyceraldehyde-3- OMP decarboxylase fructose fructose-1-phosphate reductase synthase cyclohydrolase reductase reductase aminoimidazole ribonucleotide CO phosphate dehydrogenase NADH homocysteine 2 (UMP synthase) (multiple NADPH (DHFR) NH + (AIR) (in adrenal cortex, some in gonad) (in peripheral tissue) ATP ADP glyceraldehyde 4 adenosine nucleotide salvage steps) NADH Cystathionine serine NADP+ Glycine B AIR carboxylase CO2 1,3-bisphosphoglycerate CO β-synthase 6 Fatty acid synthesis 2 cleavage uridine-5'-monophosphate serine CoA lanosterol ADP complex (UMP) protein glycerol-3-phosphate (multiple steps) Phosphoglycerate sphingosine sphingolipids NAD+ cystathionine carboxyaminoimidazole ribonucleotide modication protein kinase 10 O ATP THF (CAIR) 2 modication Serine hydroxymethyltransferase glutathione ATP CO2 Bisphosphoglycerate Phosphoglycerate Phosphoserine Phosphoserine B (SHMT) B Cystathionine + dehydrogenase transaminase 6 phosphatase 6 UMP kinase 4 NAD 8 NADPH Malonyl-CoA ACP transacylase mutase glycine nucleotides B ATP aspartate (multiple malonyl-ACP malonyl-CoA 3-phosphoglycerate 3-phopsphopyruvate 3-phosphoserine serine γ-lyase 6 (in mitochondrial matrix) fatty acyl-ACP α-ketobutyrate succinyl-CoA ADP steps) Glycerol-3-phosphate P TCA SAICAR synthetase 4 NADH 8 NADP+ palmitoyl-CoA CoA ACP i Phosphoglycerate NAD+ NADH glutamate α-ketoglutarate H O P lysine porphyrins ADP acyltransferase CoA 2 i arginine glutathione mutase Amidinotransferase cysteine H O (GPAT) ADP phosphatidylserine α-ketoglutarate 2 2 CO Pi 2 β-ketoacyl-ACP B (in mitochondrial matrix) Coenzyme A Pi UDP 7 Acetyl-CoA Malonyl-CoA Lysine-α- formate (rst cycle only) NADPH ornithine + Threonine dehydratase synthase carboxylase decarboxylase 2,3-bisphosphoglycerate 2-phosphoglycerate O2 NH ATP ceramide ketoglutarate Cysteine 4 2,3-bisphosphoglycerate succinylaminoimidazole carboxamide ribonucleotide 3 7-dehydrocholesterol CoA ACP CO reductase dioxygenase ATP 3 (7 cycles) 2 phosphatase + Nucleoside HCO - CO sphingosine NADP guanidinoacetate (SAICAR) 3 2 threonine diphosphate NADPH PP ACP β-ketoacyl-ACP Acetyl-CoA ACP Enolase saccharopine B phosphatidic acid i Long-chain Transaminase 6 ADP kinase synthase transacylase H2O + 7-Dehydro- NAD SAM cysteine β-sulnylpyruvate pyruvate + fatty β-ketoacyl-ACP acetyl-ACP acetyl-CoA Guanidinioacetate NADP GTP GDP CO Branched chain amino acid breakdown H2O cholesterol H O AMP 2 Saccharopine sulnate Adenylosuccinate lyase 2 acyl-CoA α-ketoglutarate NADH methyltransferase glutamate 2- dehydrogenase -ketoglutarate sulte (SO3 ) reductase ACP
Load more

Recommended publications
  • The Landscape of Cancer Cell Line Metabolism
    The Landscape of Cancer Cell Line Metabolism The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Li, Haoxin, Shaoyang Ning, Mahmoud Ghandi, Gregory V. Kryukov, Shuba Gopal, Amy Deik, Amanda Souza, et. al. 2019. The Landscape of Cancer Cell Line Metabolism. Nature Medicine 25, no. 5: 850-860. Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:41899268 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Nat Med Manuscript Author . Author manuscript; Manuscript Author available in PMC 2019 November 08. Published in final edited form as: Nat Med. 2019 May ; 25(5): 850–860. doi:10.1038/s41591-019-0404-8. The Landscape of Cancer Cell Line Metabolism Haoxin Li1,2, Shaoyang Ning3, Mahmoud Ghandi1, Gregory V. Kryukov1, Shuba Gopal1, Amy Deik1, Amanda Souza1, Kerry Pierce1, Paula Keskula1, Desiree Hernandez1, Julie Ann4, Dojna Shkoza4, Verena Apfel5, Yilong Zou1, Francisca Vazquez1, Jordi Barretina4, Raymond A. Pagliarini4, Giorgio G. Galli5, David E. Root1, William C. Hahn1,2, Aviad Tsherniak1, Marios Giannakis1,2, Stuart L. Schreiber1,6, Clary B. Clish1,*, Levi A. Garraway1,2,*, and William R. Sellers1,2,* 1Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA 2Department
    [Show full text]
  • Gene Symbol Gene Description ACVR1B Activin a Receptor, Type IB
    Table S1. Kinase clones included in human kinase cDNA library for yeast two-hybrid screening Gene Symbol Gene Description ACVR1B activin A receptor, type IB ADCK2 aarF domain containing kinase 2 ADCK4 aarF domain containing kinase 4 AGK multiple substrate lipid kinase;MULK AK1 adenylate kinase 1 AK3 adenylate kinase 3 like 1 AK3L1 adenylate kinase 3 ALDH18A1 aldehyde dehydrogenase 18 family, member A1;ALDH18A1 ALK anaplastic lymphoma kinase (Ki-1) ALPK1 alpha-kinase 1 ALPK2 alpha-kinase 2 AMHR2 anti-Mullerian hormone receptor, type II ARAF v-raf murine sarcoma 3611 viral oncogene homolog 1 ARSG arylsulfatase G;ARSG AURKB aurora kinase B AURKC aurora kinase C BCKDK branched chain alpha-ketoacid dehydrogenase kinase BMPR1A bone morphogenetic protein receptor, type IA BMPR2 bone morphogenetic protein receptor, type II (serine/threonine kinase) BRAF v-raf murine sarcoma viral oncogene homolog B1 BRD3 bromodomain containing 3 BRD4 bromodomain containing 4 BTK Bruton agammaglobulinemia tyrosine kinase BUB1 BUB1 budding uninhibited by benzimidazoles 1 homolog (yeast) BUB1B BUB1 budding uninhibited by benzimidazoles 1 homolog beta (yeast) C9orf98 chromosome 9 open reading frame 98;C9orf98 CABC1 chaperone, ABC1 activity of bc1 complex like (S. pombe) CALM1 calmodulin 1 (phosphorylase kinase, delta) CALM2 calmodulin 2 (phosphorylase kinase, delta) CALM3 calmodulin 3 (phosphorylase kinase, delta) CAMK1 calcium/calmodulin-dependent protein kinase I CAMK2A calcium/calmodulin-dependent protein kinase (CaM kinase) II alpha CAMK2B calcium/calmodulin-dependent
    [Show full text]
  • Screening of a Composite Library of Clinically Used Drugs and Well
    HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Pharmacol Manuscript Author Res. Author Manuscript Author manuscript; available in PMC 2017 November 01. Published in final edited form as: Pharmacol Res. 2016 November ; 113(Pt A): 18–37. doi:10.1016/j.phrs.2016.08.016. Screening of a composite library of clinically used drugs and well-characterized pharmacological compounds for cystathionine β-synthase inhibition identifies benserazide as a drug potentially suitable for repurposing for the experimental therapy of colon cancer Nadiya Druzhynaa, Bartosz Szczesnya, Gabor Olaha, Katalin Módisa,b, Antonia Asimakopoulouc,d, Athanasia Pavlidoue, Petra Szoleczkya, Domokos Geröa, Kazunori Yanagia, Gabor Töröa, Isabel López-Garcíaa, Vassilios Myrianthopoulose, Emmanuel Mikrose, John R. Zatarainb, Celia Chaob, Andreas Papapetropoulosd,e, Mark R. Hellmichb,f, and Csaba Szaboa,f,* aDepartment of Anesthesiology, The University of Texas Medical Branch, Galveston, TX, USA bDepartment of Surgery, The University of Texas Medical Branch, Galveston, TX, USA cLaboratory of Molecular Pharmacology, Department of Pharmacy, University of Patras, Greece dCenter of Clinical, Experimental Surgery & Translational Research, Biomedical Research Foundation of the Academy of Athens, Greece eNational and Kapodistrian University of Athens, School of Pharmacy, Athens, Greece fCBS Therapeutics Inc., Galveston, TX, USA Abstract Cystathionine-β-synthase (CBS) has been recently identified as a drug target for several forms of cancer. Currently no
    [Show full text]
  • United States Patent 19 11 Patent Number: 5,780,253 Subramanian Et Al
    III USOO5780253A United States Patent 19 11 Patent Number: 5,780,253 Subramanian et al. (45) Date of Patent: Jul. 14, 1998 54 SCREENING METHOD FOR DETECTION OF 4.433.999 2/1984 Hyzak ....................................... 71.03 HERBCDES 4.6–552 2/1987 Anoti et al. if O3. 4,802,912 2/1989 Baker ........................................ 7/103 Inventors: Wenkiteswaran Subramanian Danville: Anne G. Toschi. Burlingame. OTHERTHER PPUBLICATION CATIONS both of Calif. Heim et al. Pesticide Biochem & Physiol; vol. 53, pp. 138-145 (1995). 73) Assignee: Sandoz Ltd., Basel. Switzerland Hatch. MD.: Phytochem. vol. 6... pp. 115 to 119, (1967). Haworth et al. J. Agric. Food Chem, vol. 38, pp. 1271-1273. 21 Appl. No.:752.990 1990. Nishimura et al: Phytochem: vol. 34, pp. 613-615. (1993). 22 Filed: Nov. 21, 1996 Primary Examiner-Louise N. Leary Related U.S. Application Data Attorney, Agent, or Firm-Lynn Marcus-Wyner: Michael P. Morris 63 Continuation of Ser. No. 434.826, May 4, 1995, abandoned. 6 57 ABSTRACT 51 Int. Cl. ............................... C12Q 1/48: C12Q 1/32: C12Q 1/37; C12O 1/00 This invention relates to novel screening methods for iden 52 U.S. Cl. ................................. 435/15:435/18: 435/26: tifying compounds that specifically inhibit a biosynthetic 435/23: 435/4, 536/23.6:536/23.2:536/24.3 pathway in plants. Enzymes which are specifically affected 536/26.11:536/26.12:536/26.13 by the novel screening method include plant purine biosyn 58 Field of Search .................................. 435/15, 8, 26, thetic pathway enzymes and particularly the enzymes 435/23 4: 536/23.6, 23.2, 24.3, 26.1, involved in the conversion of inosine monophosphate to 26.12, 26.13 adenosine monophosphate and inosine monophosphate to guanosine monophosphate.
    [Show full text]
  • Amplitaq and Amplitaq Gold DNA Polymerase
    AmpliTaq and AmpliTaq Gold DNA Polymerase The Most Referenced Brand of DNA Polymerase in the World Date: 2005-05 Notes: Authors are listed alphabetically J. Biol. Chem. (223) Ezoe, S., I. Matsumura, et al. (2005). "GATA Transcription Factors Inhibit Cytokine-dependent Growth and Survival of a Hematopoietic Cell Line through the Inhibition of STAT3 Activity." J. Biol. Chem. 280(13): 13163-13170. http://www.jbc.org/cgi/content/abstract/280/13/13163 Although GATA-1 and GATA-2 were shown to be essential for the development of hematopoietic cells by gene targeting experiments, they were also reported to inhibit the growth of hematopoietic cells. Therefore, in this study, we examined the effects of GATA-1 and GATA-2 on cytokine signals. A tamoxifen-inducible form of GATA-1 (GATA-1/ERT) showed a minor inhibitory effect on interleukin-3 (IL-3)-dependent growth of an IL-3-dependent cell line Ba/F3. On the other hand, it drastically inhibited TPO-dependent growth and gp130-mediated growth/survival of Ba/F3. Similarly, an estradiol-inducible form of GATA-2 (GATA-2/ER) disrupted thrombopoietin (TPO)-dependent growth and gp130-mediated growth/survival of Ba/F3. As for this mechanism, we found that both GATA-1 and GATA-2 directly bound to STAT3 both in vitro and in vivo and inhibited its DNA-binding activity in gel shift assays and chromatin immunoprecipitation assays, whereas they hardly affected STAT5 activity. In addition, endogenous GATA-1 was found to interact with STAT3 in normal megakaryocytes, suggesting that GATA-1 may inhibit STAT3 activity in normal hematopoietic cells.
    [Show full text]
  • Copyright by Jeremy Daniel O'connell 2012
    Copyright by Jeremy Daniel O’Connell 2012 The Dissertation Committee for Jeremy Daniel O’Connell Certifies that this is the approved version of the following dissertation: Systemic Protein Aggregation in Stress and Aging Restructures Cytoplasmic Architecture Committee: Edward Marcotte, Supervisor Dean Appling Andrew Ellington Makkuni Jayaram Scott Stevens Systemic Protein Aggregation in Stress and Aging Restructures Cytoplasmic Architecture by Jeremy Daniel O’Connell, B.S. Dissertation Presented to the Faculty of the Graduate School of The University of Texas at Austin in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy The University of Texas at Austin September 2012 Dedication Cytisus laburnum, simul vincet omnem To my dad and mom who encouraged and enabled my education with countless sacrifices, I promised this graduation would be the one we would attend, and I am truly sorry I was not swift enough to make that possible. Acknowledgements Foremost, I thank my advisor Edward Marcotte, for not just a second lease on a life in science but one in an amazing lab environment. His intellectual rigor, enduring patience, amazing work ethic, and enthusiasm for discovery were an inspiration. I thank my collaborators in this project: Gwen Stovall, Alice Zhao, Gabe Wu, and Mark Tsechansky for their comradery and support on this great adventure. I thank the talented undergraduates: Maguerite West-Driga, Ariel Royall, and Tyler McDonald who stuck with me. Each of you will soon be a better scientist than I ever will, and I hope you enjoyed and learned from our research together nearly as much as I did.
    [Show full text]
  • IMPDH2: a New Gene Associated with Dominant Juvenile-Onset Dystonia-Tremor Disorder
    www.nature.com/ejhg BRIEF COMMUNICATION OPEN IMPDH2: a new gene associated with dominant juvenile-onset dystonia-tremor disorder 1,8 1,8 2 3 1,4 2 5 Anna Kuukasjärvi , Juan✉ C. Landoni , Jyrki Kaukonen , Mika Juhakoski , Mari Auranen , Tommi Torkkeli , Vidya Velagapudi and Anu Suomalainen 1,6,7 © The Author(s) 2021 The aetiology of dystonia disorders is complex, and next-generation sequencing has become a useful tool in elucidating the variable genetic background of these diseases. Here we report a deleterious heterozygous truncating variant in the inosine monophosphate dehydrogenasegene(IMPDH2) by whole-exome sequencing, co-segregating with a dominantly inherited dystonia-tremor disease in a large Finnish family. We show that the defect results in degradation of the gene product, causing IMPDH2 deficiency in patient cells. IMPDH2 is the first and rate-limiting enzyme in the de novo biosynthesis of guanine nucleotides, a dopamine synthetic pathway previously linked to childhood or adolescence-onset dystonia disorders. We report IMPDH2 as a new gene to the dystonia disease entity. The evidence underlines the important link between guanine metabolism, dopamine biosynthesis and dystonia. European Journal of Human Genetics; https://doi.org/10.1038/s41431-021-00939-1 INTRODUCTION The disease-onset was between 9 and 20 years of age. Table 1 Dystonias are rare movement disorders characterised by sustained or summarises the clinical presentations. intermittent muscle contractions causing abnormal, often repetitive, movements and/or postures. Dystonia can manifest as an isolated Case report symptom or combined with e.g. parkinsonism or myoclonus [1]. While Patient II-6 is a 46-year-old woman.
    [Show full text]
  • 35 Disorders of Purine and Pyrimidine Metabolism
    35 Disorders of Purine and Pyrimidine Metabolism Georges van den Berghe, M.- Françoise Vincent, Sandrine Marie 35.1 Inborn Errors of Purine Metabolism – 435 35.1.1 Phosphoribosyl Pyrophosphate Synthetase Superactivity – 435 35.1.2 Adenylosuccinase Deficiency – 436 35.1.3 AICA-Ribosiduria – 437 35.1.4 Muscle AMP Deaminase Deficiency – 437 35.1.5 Adenosine Deaminase Deficiency – 438 35.1.6 Adenosine Deaminase Superactivity – 439 35.1.7 Purine Nucleoside Phosphorylase Deficiency – 440 35.1.8 Xanthine Oxidase Deficiency – 440 35.1.9 Hypoxanthine-Guanine Phosphoribosyltransferase Deficiency – 441 35.1.10 Adenine Phosphoribosyltransferase Deficiency – 442 35.1.11 Deoxyguanosine Kinase Deficiency – 442 35.2 Inborn Errors of Pyrimidine Metabolism – 445 35.2.1 UMP Synthase Deficiency (Hereditary Orotic Aciduria) – 445 35.2.2 Dihydropyrimidine Dehydrogenase Deficiency – 445 35.2.3 Dihydropyrimidinase Deficiency – 446 35.2.4 Ureidopropionase Deficiency – 446 35.2.5 Pyrimidine 5’-Nucleotidase Deficiency – 446 35.2.6 Cytosolic 5’-Nucleotidase Superactivity – 447 35.2.7 Thymidine Phosphorylase Deficiency – 447 35.2.8 Thymidine Kinase Deficiency – 447 References – 447 434 Chapter 35 · Disorders of Purine and Pyrimidine Metabolism Purine Metabolism Purine nucleotides are essential cellular constituents 4 The catabolic pathway starts from GMP, IMP and which intervene in energy transfer, metabolic regula- AMP, and produces uric acid, a poorly soluble tion, and synthesis of DNA and RNA. Purine metabo- compound, which tends to crystallize once its lism can be divided into three pathways: plasma concentration surpasses 6.5–7 mg/dl (0.38– 4 The biosynthetic pathway, often termed de novo, 0.47 mmol/l). starts with the formation of phosphoribosyl pyro- 4 The salvage pathway utilizes the purine bases, gua- phosphate (PRPP) and leads to the synthesis of nine, hypoxanthine and adenine, which are pro- inosine monophosphate (IMP).
    [Show full text]
  • The Regulation of Carbamoyl Phosphate Synthetase-Aspartate Transcarbamoylase-Dihydroorotase (Cad) by Phosphorylation and Protein-Protein Interactions
    THE REGULATION OF CARBAMOYL PHOSPHATE SYNTHETASE-ASPARTATE TRANSCARBAMOYLASE-DIHYDROOROTASE (CAD) BY PHOSPHORYLATION AND PROTEIN-PROTEIN INTERACTIONS Eric M. Wauson A dissertation submitted to the faculty of the University of North Carolina at Chapel Hill in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Department of Pharmacology. Chapel Hill 2007 Approved by: Lee M. Graves, Ph.D. T. Kendall Harden, Ph.D. Gary L. Johnson, Ph.D. Aziz Sancar M.D., Ph.D. Beverly S. Mitchell, M.D. 2007 Eric M. Wauson ALL RIGHTS RESERVED ii ABSTRACT Eric M. Wauson: The Regulation of Carbamoyl Phosphate Synthetase-Aspartate Transcarbamoylase-Dihydroorotase (CAD) by Phosphorylation and Protein-Protein Interactions (Under the direction of Lee M. Graves, Ph.D.) Pyrimidines have many important roles in cellular physiology, as they are used in the formation of DNA, RNA, phospholipids, and pyrimidine sugars. The first rate- limiting step in the de novo pyrimidine synthesis pathway is catalyzed by the carbamoyl phosphate synthetase II (CPSase II) part of the multienzymatic complex Carbamoyl phosphate synthetase, Aspartate transcarbamoylase, Dihydroorotase (CAD). CAD gene induction is highly correlated to cell proliferation. Additionally, CAD is allosterically inhibited or activated by uridine triphosphate (UTP) or phosphoribosyl pyrophosphate (PRPP), respectively. The phosphorylation of CAD by PKA and ERK has been reported to modulate the response of CAD to allosteric modulators. While there has been much speculation on the identity of CAD phosphorylation sites, no definitive identification of in vivo CAD phosphorylation sites has been performed. Therefore, we sought to determine the specific CAD residues phosphorylated by ERK and PKA in intact cells.
    [Show full text]
  • Metabolism of Purines and Pyrimidines in Health and Disease
    39th Meeting of the Polish Biochemical Society Gdañsk 16–20 September 2003 SESSION 6 Metabolism of purines and pyrimidines in health and disease Organized by A. C. Sk³adanowski, A. Guranowski 182 Session 6. Metabolism of purines and pyrimidines in health and disease 2003 323 Lecture The role of DNA methylation in cytotoxicity mechanism of adenosine analogues in treatment of leukemia Krystyna Fabianowska-Majewska Zak³ad Chemii Medycznej IFiB, Uniwersytet Medyczny, ul. Mazowiecka 6/8, 92 215 £ódŸ Changes in DNA methylation have been recognized tory effects of cladribine and fludarabine on DNA as one of the most common molecular alterations in hu- methylation, after 48 hr growth of K562 cells with the man neoplastic diseases and hypermethylation of drugs, are non-random and affect mainly CpG rich is- gene-promoter regions is one of the most frequent lands or CCGG sequences but do not affect sepa- mechanisms of the loss of gene functions. For this rea- rately-located CpG sequences. The analysis showed son, DNA methylation may be a tool for detection of that cladribine (0.1 mM) reduced the methylated early cell transformations as well as predisposition to cytosines in CpG islands and CCGG sequences to a sim- metastasis process. Moreover, DNA methylation seems ilar degree. The inhibition of cytosine methylation by to be a promissing target for new preventive and thera- fludarabine (3 mM) was observed mainly in CCGG se- peutic strategies. quences, sensitive to HpaII, but the decline in the meth- Our studies on DNA methylation and cytotoxicity ylated cytosine, located in CpG island was 2-fold lower mechanism of antileukemic drugs, cladribine and than that with cladribine.
    [Show full text]
  • CYP2A6) by P53
    Transcriptional Regulation of Human Stress Responsive Cytochrome P450 2A6 (CYP2A6) by p53 Hao Hu M.Biotech. (Biotechnology) 2012 The University of Queensland B.B.A. 2009 University of Electronic Science and Technology of China B.Sc. (Pharmacy) 2009 University of Electronic Science and Technology of China A thesis submitted for the degree of Doctor of Philosophy at The University of Queensland in 2016 School of Medicine ABSTRACT Human cytochrome P450 (CYP) 2A6 is highly expressed in the liver and the encoding gene is regulated by various stress activated transcription factors, such as the nuclear factor (erythroid-derived 2)-like 2 (Nrf-2). Unlike the other xenobiotic metabolising CYP enzymes (XMEs), CYP2A6 only plays a minor role in xenobiotic metabolism. The CYP2A6 is highly induced by multiple forms of cellular stress conditions, where XMEs expression is normally inhibited. Recent findings suggest that the CYP2A6 plays an important role in regulating BR homeostasis. A computer based sequence analysis on the 3 kb proximate CYP2A6 promoter revealed several putative binding sites for p53, a protein that mediates regulation of antioxidant and apoptosis pathways. In this study, the role of p53 in CYP2A6 gene regulation is demonstrated. The site closest to transcription start site (TSS) is highly homologous with the p53 consensus sequence. The p53 responsiveness of this site was confirmed by transfections with various stepwise deleted of CYP2A6-5’-Luc constructs containing the putative p53RE. Deletion of the putative p53RE resulted in a total abolishment of p53 responsiveness of CYP2A6 promoter. Specific binding of p53 to the putative p53RE was detected by electrophoresis mobility shift assay.
    [Show full text]
  • Molecular Analysis of the Aldolase B Gene in Patients with Hereditary
    1of8 J Med Genet: first published as 10.1136/jmg.39.9.e56 on 1 September 2002. Downloaded from ONLINE MUTATION REPORT Molecular analysis of the aldolase B gene in patients with hereditary fructose intolerance from Spain J C Sánchez-Gutiérrez, T Benlloch, M A Leal, B Samper, I García-Ripoll, J E Felíu ............................................................................................................................. J Med Genet 2002;39:e56 (http://www.jmedgenet.com/cgi/content/full/39/9/e56) ereditary fructose intolerance (HFI) is an autosomal resident in the following regions: Madrid (11 families), Anda- recessive metabolic disorder caused by aldolase (fructo- lusia (4), Galicia (3), Estremadura (1), Valencia (1), and Hsediphosphate aldolase, EC 4.1.2.13) B deficiency.1 The Spanish possessions in North Africa (1). HFI diagnosis was B isoform of aldolase is critical for the metabolism of based on enzymatic studies (deficient aldolase B activity in exogenous fructose by the liver, kidney, and intestine, since it hepatic biopsies from 16 patients) or clinical symptoms (six can use fructose-1-phosphate as substrate at physiological patients). Another six subjects were suspected to suffer from concentrations, unlike aldolases A and C. Affected subjects HFI on the basis of dietary intolerance with episodes sugges- suffer abdominal pain, vomiting, and hypoglycaemia after the tive of hypoglycaemia and occurrence of the disease in their ingestion of fructose, sucrose, or sorbitol. Continued ingestion first degree relatives. of noxious sugars causes hepatic and renal injury, which eventually leads to liver cirrhosis and sometimes death, Reagents particularly in small infants.1 Treatment consists of strict Thermostable DNA polymerase, deoxynucleotides, and gen- elimination of fructose, sucrose, and sorbitol from the diet eral PCR products were from Biotools (Madrid, Spain).
    [Show full text]